Rutgers Cancer Institute of New Jersey | Strategic Alliance Partners

As New Jersey’s only National Cancer Institute (NCI) – designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – these cutting-edge therapies are available to adult and pediatric patients. Some of these treatments are fueled by onsite research in which physicians and scientists work side by side to advance our understanding of cancer and transform laboratory discoveries into clinical practice.

Latest from Rutgers Cancer Institute of New Jersey

Dr. Bannerji on the Toxicity Profile of Odronextamab in Non-Hodgkin Lymphoma

January 06, 2021

Video

Rajat Bannerji, MD, PhD, discusses the toxicity profile of odronextamab in non-Hodgkin lymphoma.

Bispecific Antibody Is Highly Active in Relapsed/Refractory Non-Hodgkin Lymphoma

April 20, 2020

Article

Rajat Bannerji, MD, PhD, discusses the clinical activity of the bispecific antibody REGN1979 in patients with non-Hodgkin lymphoma.

Dr. Hochster on Take-Home Message of the POLO Trial in Pancreatic Cancer

October 02, 2019

Video

Howard S. Hochster, MD, FACP, discusses important takeaways from the randomized, double-blind, phase III POLO trial in pancreatic cancer.

Dr. Hochster on the Safety Analysis of TAS-102 in CRC and Gastric/GEJ Cancer

August 08, 2019

Video

Howard Hochster, MD, FACP, associate director for clinical research and director, Gastrointestinal Oncology, Rutgers Cancer Institute of New Jersey, director of oncology research, RWJBarnabas Health, discusses the safety analysis of TAS-102 in metastatic colorectal cancer and metastatic gastric/gastroesophageal junction cancer.

Dr. Malhotra on Pembrolizumab During Concurrent Chemoradiation in NSCLC

July 09, 2019

Video

Jyoti Malhotra, MD, MPH, discusses a phase I multicenter trial of PD-1 blockade with pembrolizumab with concurrent chemoradiation in patients with locally advanced, unresectable non–small cell lung cancer.

$15.1M Awarded to Rutgers Cancer Institute of New Jersey for Redesignation as the State's Only Comprehensive Cancer Center

April 23, 2019

Article

Rutgers Cancer Institute of New Jersey, the state’s only Comprehensive Cancer Center as recognized by the National Cancer Institute, has been awarded a $15.1 million grant as part of its successful 2019 redesignation.